Early diagnosis of transthyretin cardiac amyloidosis

Disease modifying therapies for ATTR transthyretin cardiac amyloidosis (ATTR-CA) promises to make a previously untreatable disease manageable. In general, cardiac amyloidosis of any type has been shown to be underdiagnosed or diagnosed late in the disease process. Our goal of the study is to identify African American (AA) patients who are carrying the V122I ATTR mutation with mild left ventricular hypertrophy and other patients who might have wild type ATTR (senile amyloidosis) who presented with carpal tunnel syndrome for surgical intervention, or lone atrial fibrillations, or other clinical suspicion. We would like to establish non-invasive methods using cardiac MRI and radionuclide imaging techniques (pyrophosphate technetium scan (PYP) to detect early stage CA infiltration in the heart.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All